Vertex Pharmaceuticals Incorporated (VRTX)

NMS – Real Time Price. Currency in USD

527.77

-1.88 (-0.35%)

Market open: Aug 12, 2026, 10:46 AM EDT

529.99

+0.34 (0.06%)

Previous after-hours: Aug 11, 2026, 7:55 PM EDT

10.08.2026

Why Vertex Pharma Popped, As A Key Rival Plummeted 90%

Vertex stock surged Monday after its competitor, Sionna Therapeutics, missed the mark for its highly anticipated cystic fibrosis treatment.

07.08.2026

Could 1 Tiny Biotech Topple Vertex Pharmaceuticals' Cystic Fibrosis Empire?

Vertex Pharmaceuticals could face competition in its most important market by far. The company is preparing for that by diversifying its lineup and pipeline.

04.08.2026

Why Vertex Pharmaceuticals Stock Ticked Higher on Tuesday

Its sales rose at a double-digit rate; net profit growth was more modest. There's another development with the company more worth monitoring, however.

04.08.2026

VRTX's Q2 Earnings Lag Estimates, Revenues Top, 2026 Sales View Raised

Vertex's Q2 earnings miss estimates, but revenues beat. It lifts its 2026 sales outlook, and sees growing contributions from newer products.

04.08.2026

VRTX Q2 Earnings Call Highlights Launch Momentum & Higher Outlook

Vertex raises its 2026 revenue outlook as CF growth, newer products and a near-term renal launch strengthen its diversification push.

04.08.2026

Vertex Pharmaceuticals: A Transition Year Into A Multi-Franchise Growth Story

Vertex Pharmaceuticals is executing a pivotal transition year, evolving from a CF-dominated biotech to a multi-franchise growth platform. 2Q26 revenue rose 12% to $3.33 billion, with strong CF performance and early scaling of Casgevy and Journvax supporting raised FY26 guidance to $13.1–$13.2 billion. VRTX is aggressively reinvesting in pipeline and commercial launches, leveraging a $13.6 billion cash position and diversifying with the Crinetics acquisition.

04.08.2026

Vertex Pharmaceuticals Incorporated (VRTX) Q2 2026 Earnings Call Transcript

Videos

No Data

There is no data to display

Press releases

03.08.2026

Vertex Reports Second Quarter 2026 Financial Results

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the second quarter ended June 30, 2026, and updated its full year 2026 revenue guidance. “Vertex delivered excellent second quarter results, expanding our leadership in cystic fibrosis; delivering strong revenue growth in sickle cell disease, beta thalassemia, and acute pain; and with the pending acquisition of Crinetics, adding rare endocrine diseases as our fifth pilla.

Vertex Pharmaceuticals Incorporated (VRTX)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Vertex Pharmaceuticals Incorporated (VRTX)

Why Vertex Pharma Popped, As A Key Rival Plummeted 90%

Could 1 Tiny Biotech Topple Vertex Pharmaceuticals' Cystic Fibrosis Empire?

Why Vertex Pharmaceuticals Stock Ticked Higher on Tuesday

VRTX's Q2 Earnings Lag Estimates, Revenues Top, 2026 Sales View Raised

VRTX Q2 Earnings Call Highlights Launch Momentum & Higher Outlook

Vertex Pharmaceuticals: A Transition Year Into A Multi-Franchise Growth Story

Vertex Pharmaceuticals Incorporated (VRTX) Q2 2026 Earnings Call Transcript

Videos

No Data

Press releases

Vertex Reports Second Quarter 2026 Financial Results

Why Vertex Pharma Popped, As A Key Rival Plummeted 90%

Could 1 Tiny Biotech Topple Vertex Pharmaceuticals' Cystic Fibrosis Empire?

Why Vertex Pharmaceuticals Stock Ticked Higher on Tuesday

VRTX's Q2 Earnings Lag Estimates, Revenues Top, 2026 Sales View Raised

VRTX Q2 Earnings Call Highlights Launch Momentum & Higher Outlook

Vertex Pharmaceuticals: A Transition Year Into A Multi-Franchise Growth Story

Vertex Pharmaceuticals Incorporated (VRTX) Q2 2026 Earnings Call Transcript

Videos

No Data

Press releases

Vertex Reports Second Quarter 2026 Financial Results

Search stocks

Vertex Pharmaceuticals Incorporated (VRTX)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Vertex Pharmaceuticals Incorporated (VRTX)

Why Vertex Pharma Popped, As A Key Rival Plummeted 90%

Could 1 Tiny Biotech Topple Vertex Pharmaceuticals' Cystic Fibrosis Empire?

Why Vertex Pharmaceuticals Stock Ticked Higher on Tuesday

VRTX's Q2 Earnings Lag Estimates, Revenues Top, 2026 Sales View Raised

VRTX Q2 Earnings Call Highlights Launch Momentum & Higher Outlook

Vertex Pharmaceuticals: A Transition Year Into A Multi-Franchise Growth Story

Vertex Pharmaceuticals Incorporated (VRTX) Q2 2026 Earnings Call Transcript

Videos

No Data

Press releases

Vertex Reports Second Quarter 2026 Financial Results

Why Vertex Pharma Popped, As A Key Rival Plummeted 90%

Could 1 Tiny Biotech Topple Vertex Pharmaceuticals' Cystic Fibrosis Empire?

Why Vertex Pharmaceuticals Stock Ticked Higher on Tuesday

VRTX's Q2 Earnings Lag Estimates, Revenues Top, 2026 Sales View Raised

VRTX Q2 Earnings Call Highlights Launch Momentum & Higher Outlook

Vertex Pharmaceuticals: A Transition Year Into A Multi-Franchise Growth Story

Vertex Pharmaceuticals Incorporated (VRTX) Q2 2026 Earnings Call Transcript

Videos

No Data

Press releases

Vertex Reports Second Quarter 2026 Financial Results